ESMO 2014 - Prostate Cancer

Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent